Next-Generation Techniques for Discovering Human Monoclonal Antibodies


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term next-generation antibody-discovery platforms has already been established in the literature to refer to these approaches. Our review focuses on describing the results obtained by these methods.

About the authors

A. A. Lushova

Institute of Immunology

Email: avfilat@yandex.ru
Russian Federation, Moscow, 115478

M. G. Biazrova

Institute of Immunology

Email: avfilat@yandex.ru
Russian Federation, Moscow, 115478

A. G. Prilipov

Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology

Email: avfilat@yandex.ru
Russian Federation, Moscow, 123098

G. K. Sadykova

Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology

Email: avfilat@yandex.ru
Russian Federation, Moscow, 123098

T. A. Kopylov

Orekhovich Institute of Biomedical Chemistry

Email: avfilat@yandex.ru
Russian Federation, Moscow, 119121

A. V. Filatov

Institute of Immunology

Author for correspondence.
Email: avfilat@yandex.ru
Russian Federation, Moscow, 115478

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Pleiades Publishing, Inc.